Unicycive Therapeutics’ (UNCY) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY) in a research report report published on Tuesday morning,Benzinga reports. The firm currently has a $2.50 price objective on the stock.

Separately, Benchmark reiterated a “speculative buy” rating and issued a $3.00 target price on shares of Unicycive Therapeutics in a research report on Friday, September 6th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Unicycive Therapeutics has a consensus rating of “Buy” and an average target price of $5.13.

Unicycive Therapeutics Trading Down 6.3 %

Shares of NASDAQ UNCY opened at $0.45 on Tuesday. The business has a 50-day moving average of $0.43 and a 200-day moving average of $0.56. The firm has a market capitalization of $42.27 million, a price-to-earnings ratio of -0.43 and a beta of 2.29. Unicycive Therapeutics has a 12 month low of $0.20 and a 12 month high of $1.82.

Unicycive Therapeutics (NASDAQ:UNCY) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.08. On average, analysts predict that Unicycive Therapeutics will post -0.26 earnings per share for the current year.

Institutional Investors Weigh In On Unicycive Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Virtu Financial LLC bought a new position in shares of Unicycive Therapeutics during the 1st quarter valued at $36,000. Bleakley Financial Group LLC bought a new stake in Unicycive Therapeutics in the third quarter worth $33,000. BVF Inc. IL boosted its position in Unicycive Therapeutics by 70.5% during the first quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock valued at $4,984,000 after buying an additional 1,493,462 shares during the period. Acuta Capital Partners LLC bought a new position in shares of Unicycive Therapeutics during the third quarter valued at about $807,000. Finally, Walleye Capital LLC purchased a new position in shares of Unicycive Therapeutics in the third quarter worth about $2,040,000. 40.42% of the stock is currently owned by institutional investors.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.